binx health requests EUA for CRISPR-based test for COVID-19
Industry News: binx health submits request for Emergency Use Authorization for first CRISPR-based point-of-care test for COVID-19 Platform poised to be first CLIA-waived CRISPR-based, point-of-care COVID-19 device with central-lab performance, developed in collaboration with Sherlock Biosciences 18 May 2021 binx health has announced the submission of an Emergency Use Authorization (EUA) request to the U.S. Food and Drug Administration (FDA) for the first CLIA-waived CRISPR-based point-of-care (...
Jeffrey Luber Sherlock Biosciences Rahul Dhanda Sherlock Bioscience Clinical Laboratory Improvement Amendments Drug Administration
Source: selectscience.net